Lipid-dendrimer hybrid nanosystem as a novel delivery system for paclitaxel to treat ovarian cancer

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 438-446

  Liu, Yuanjie ^a   Ng, Yiwei ^a   Toh, Ming R ^a   Chiu, Gigi N C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Dendrimer; Drug delivery system; Lipid; Liposome; Ovarian cancer; Paclitaxel

Indexed keywords

CELL MEMBRANES; DENDRIMERS; DISEASES; ENCAPSULATION; LIPIDS; LIPOSOMES;

1 ,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHOCHOLINE; ANTICANCER ACTIVITIES; DRUG DELIVERY SYSTEM; ENCAPSULATION EFFICIENCY; FLUORESCENCE CONFOCAL MICROSCOPY; OVARIAN CANCER CELLS; OVARIAN CANCERS; PACLITAXEL;

NANOSYSTEMS;

ANTINEOPLASTIC AGENT; DENDRIMER; DIPALMITOYLPHOSPHATIDYLCHOLINE; LACTATE DEHYDROGENASE; LIPID; NANOCARRIER; PACLITAXEL; POLYAMIDOAMINE; DRUG CARRIER; NANOPARTICLE; NYLON; PAMAM-G4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CELL CULTURE; CELL MEMBRANE; CELL VIABILITY ASSAY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DILUTION; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG UPTAKE; ENCAPSULATION; FEMALE; HYBRID; HYDRODYNAMICS; IN VITRO STUDY; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; ROOM TEMPERATURE; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CELL SURVIVAL; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG FORMULATION; DRUG SCREENING; HUMAN; METABOLISM; NANOTECHNOLOGY; OVARIAN NEOPLASMS; PATHOLOGY; SCID MOUSE; SOLUBILITY; TIME FACTOR; TUMOR CELL LINE;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL SURVIVAL; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; HUMANS; MICE, SCID; NANOPARTICLES; NANOTECHNOLOGY; NYLONS; OVARIAN NEOPLASMS; PACLITAXEL; SOLUBILITY; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946574753     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.11.004     Document Type: Article

References (50)

1. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol. Pharm. 8 2011 2101 2141
2. A.M. Glauert, J.T. Dingle, and J.A. Lucy Action of saponin on biological cell membranes Nature 196 1962 953 955
3. A.D. Bangham, and R.W. Horne Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope J. Mol. Biol. 8 1964 (660-IN610)
4. D.A. Tomalia, H. Baker, J. Dewald, M. Hall, G. Kallos, S. Martin, J. Roeck, J. Ryder, and P. Smith A new class of polymers: starburst-dendritic macromolecules Polym. J. 17 1985 117 132
5. T. Imae Physicochemical properties of dendrimers and dendrimer complexes Dendrimer-Based Drug Delivery Systems 2012 John Wiley & Sons, Inc. 55 92
6. C.M. Paleos, D. Tsiourvas, Z. Sideratou, and A. Pantos Formation of artificial multicompartment vesosome and dendrosome as prospected drug and gene delivery carriers J. Control. Release 170 2013 141 152
7. K. Gardikis, C. Tsimplouli, K. Dimas, M. Micha-Screttas, and C. Demetzos New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers Int. J. Pharm. 402 2010 231 237
8. K. Gardikis, S. Hatziantoniou, M. Bucos, D. Fessas, M. Signorelli, T. Felekis, M. Zervou, C.G. Screttas, B.R. Steele, M. Ionov, M. Micha-Screttas, B. Klajnert, M. Bryszewska, and C. Demetzos New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy J. Pharm. Sci. 99 2010 3561 3571
9. A. Papagiannaros, K. Dimas, G.T. Papaioannou, and C. Demetzos Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines Int. J. Pharm. 302 2005 29 38
10. A.J. Khopade, F. Caruso, P. Tripathi, S. Nagaich, and N.K. Jain Effect of dendrimer on entrapment and release of bioactive from liposomes Int. J. Pharm. 232 2002 157 162
11. A. Kwok, G.A. Eggimann, J.-L. Reymond, T. Darbre, and F. Hollfelder Peptide dendrimer/lipid hybrid systems are efficient DNA transfection reagents: structure-activity relationships highlight the role of charge distribution across dendrimer generations ACS Nano 7 2013 4668 4682
12. S. Han, Z. Cai, L. Peng, Z. Li, H.-B. Zhou, X.-Q. Li, S.-Z. Fang, Z.-H. Huang, and D.-X. Cui Polyamidoamine dendrimer liposome-mediated survivin antisense oligonucleotide inhibits hepatic cancer cell proliferation by inducing apoptosis Tumor Biol. 35 2014 5013 5019
13. W. Lorenz, H.J. Reimann, A. Schmal, P. Dormann, B. Schwarz, E. Neugebauer, and A. Doenicke Histamine release in dogs by Cremophor El® and its derivatives: oxethylated oleic acid is the most effective constituent Agents Actions 7 1977 63 67
14. R.T. Dorr Pharmacology and toxicology of Cremophor EL diluent Ann. Pharmacother. 28 1994 S11 S14
15. J. Szebeni, C.R. Alving, and F.M. Muggia Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study J. Natl. Cancer Inst. 90 1998 300 306
16. C.H. Fiske, and Y. Subbarow The colorimetric determination of phosphorus J. Biol. Chem. 66 1925 375 400
17. R.A. Rajewski, D.G. Kosednar, T.A. Matches, O.S. Wong, K. Burchett, and K. Thakker Stereo-specific analysis of a novel protein kinase C inhibitor J. Pharm. Biomed. Anal. 13 1995 247 253
18. T. Higuchi Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices J. Pharm. Sci. 52 1963 1145 1149
19. N.A. Peppas, and J.J. Sahlin A simple equation for the description of solute release. III. Coupling of diffusion and relaxation Int. J. Pharm. 57 1989 169 172
20. T. Alfrey, E.F. Gurnee, and W.G. Lloyd Diffusion in glassy polymers J. Polym. Sci. C Polym. Symp. 12 1966 249 261
21. T.C. Chou Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies Pharmacol. Rev. 58 2006 621 681
22. D. Needham, and R.S. Sarpal Binding of paclitaxel to lipid interfaces: correlations with interface compliance J. Liposome Res. 8 1998 147 163
23. T.-C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res. 70 2010 440 446
24. S. Hong, A.U. Bielinska, A. Mecke, B. Keszler, J.L. Beals, X. Shi, L. Balogh, B.G. Orr, J.R. Baker Jr., and M.M. Banaszak Holl Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport Bioconjug. Chem. 15 2004 774 782
25. I.M. Shaikh, K.-B. Tan, A. Chaudhury, Y. Liu, B.-J. Tan, B.M.J. Tan, and G.N.C. Chiu Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft J. Control. Release 172 2013 852 861
26. X. Zhang, H.M. Burt, G. Mangold, D. Dexter, D. Von Hoff, L. Mayer, and W.L. Hunter Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel Anti-Cancer Drugs 8 1997 696 701
27. K. Gardikis, S. Hatziantoniou, K. Viras, M. Wagner, and C. Demetzos A DSC and Raman spectroscopy study on the effect of PAMAM dendrimer on DPPC model lipid membranes Int. J. Pharm. 318 2006 118 123
28. S.K. Dordunoo, and H.M. Burt Solubility and stability of taxol: effects of buffers and cyclodextrins Int. J. Pharm. 133 1996 191 201
29. T. Ooya, J. Lee, and K. Park Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization, and hydrotropic solubilization of paclitaxel Bioconjug. Chem. 15 2004 1221 1229
30. A. Sharma, and R.M. Straubinger Novel taxol formulations: preparation and characterization of taxol-containing liposomes Pharm. Res. 11 1994 889 896
31. L. Boni, J. Portnoff, Taxane-Containing Phosphatidylcholine Liposomes, in, Google Patents, 1997.
32. A. Mecke, I.J. Majoros, A.K. Patri, J.R. Baker Jr., M.M. Holl, and B.G. Orr Lipid bilayer disruption by polycationic polymers: the roles of size and chemical functional group Langmuir 21 2005 10348 10354
33. C.V. Kelly, M.G. Liroff, L.D. Triplett, P.R. Leroueil, D.G. Mullen, J.M. Wallace, S. Meshinchi, J.R. Baker, B.G. Orr, and M.M. Banaszak Holl Stoichiometry and structure of poly(amidoamine) dendrimer-lipid complexes ACS Nano 3 2009 1886 1896
34. H. Lee, and R.G. Larson Molecular dynamics simulations of PAMAM dendrimer-induced pore formation in DPPC bilayers with a coarse-grained model J. Phys. Chem. B 110 2006 18204 18211
35. C.V. Kelly, P.R. Leroueil, E.K. Nett, J.M. Wereszczynski, J.R. Baker Jr., B.G. Orr, M.M. Banaszak Holl, and I. Andricioaei Poly(amidoamine) dendrimers on lipid bilayers I: free energy and conformation of binding J. Phys. Chem. B 112 2008 9337 9345
36. C.V. Kelly, P.R. Leroueil, B.G. Orr, M.M. Banaszak Holl, and I. Andricioaei Poly(amidoamine) dendrimers on lipid bilayers II: effects of bilayer phase and dendrimer termination J. Phys. Chem. B 112 2008 9346 9353
37. S. Berenyi, J. Mihaly, A. Wacha, O. Toke, and A. Bota A mechanistic view of lipid membrane disrupting effect of PAMAM dendrimers Colloids Surf. B Biointerfaces 118 2014 164 171
38. G.N. Chiu, M.Y. Wong, L.U. Ling, I.M. Shaikh, K.B. Tan, A. Chaudhury, and B.J. Tan Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities Curr. Drug Metab. 10 2009 861 874
39. P.C. Naha, M. Davoren, F.M. Lyng, and H.J. Byrne Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells Toxicol. Appl. Pharmacol. 246 2010 91 99
40. S.P. Mukherjee, and H.J. Byrne Polyamidoamine dendrimer nanoparticle cytotoxicity, oxidative stress, caspase activation and inflammatory response: experimental observation and numerical simulation Nanomedicine 9 2013 202 211
41. S.P. Mukherjee, F.M. Lyng, A. Garcia, M. Davoren, and H.J. Byrne Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells Toxicol. Appl. Pharmacol. 248 2010 259 268
42. F.M. Muggia New and emerging intraperitoneal (IP) drugs for ovarian cancer treatment Semin. Oncol. 33 2006 S18 S24
43. K. Fujiwara, D. Armstrong, M. Morgan, and M. Markman Principles and practice of intraperitoneal chemotherapy for ovarian cancer Int. J. Gynecol. Cancer 17 2007 1 20
44. A. Banzato, S. Bobisse, M. Rondina, D. Renier, F. Bettella, G. Esposito, L. Quintieri, L. Melendez-Alafort, U. Mazzi, P. Zanovello, and A. Rosato A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity Clin. Cancer Res. 14 2008 3598 3606
45. K. Xiao, J. Luo, W.L. Fowler, Y. Li, J.S. Lee, L. Xing, R.H. Cheng, L. Wang, and K.S. Lam A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer Biomaterials 30 2009 6006 6016
46. N. Sato, H. Kobayashi, T. Saga, Y. Nakamoto, T. Ishimori, K. Togashi, Y. Fujibayashi, J. Konishi, and M.W. Brechbiel Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice Clin. Cancer Res. 7 2001 3606 3612
47. R.R. Arvizo, O.R. Miranda, D.F. Moyano, C.A. Walden, K. Giri, R. Bhattacharya, J.D. Robertson, V.M. Rotello, J.M. Reid, and P. Mukherjee Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles PLoS One 6 2011 e24374
48. L. Harivardhan Reddy, R.K. Sharma, K. Chuttani, A.K. Mishra, and R.S. Murthy Influence of administration route on tumor uptake and biodistribution of etoposide loaded solid lipid nanoparticles in Dalton's lymphoma tumor bearing mice J. Control. Release 105 2005 185 198
49. A. Akesson, M. Cardenas, G. Elia, M.P. Monopoli, and K.A. Dawson The protein corona of dendrimers: PAMAM binds and activates complement proteins in human plasma in a generation dependent manner RSC Adv. 2 2012 11245 11248
50. C. Plank, K. Mechtler, F.C. Szoka Jr., and E. Wagner Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery Hum. Gene Ther. 7 1996 1437 1446